AIMC Topic: Antipsychotic Agents

Clear Filters Showing 1 to 10 of 39 articles

Study protocol for optimising antipsychotic prescribing among hospitalised patients in the acute care setting in Scotland: a national retrospective cohort study.

BMJ open
INTRODUCTION: Prescribing high-dose antipsychotics is typically reserved for individuals with treatment-resistant severe mental illnesses, such as schizophrenia, bipolar disorder and psychotic depression. It carries an increased risk of adverse drug ...

Multi-omics reveal critical roles of phosphatidylcholine and sphingomyelin in antipsychotic efficacy for schizophrenia.

Signal transduction and targeted therapy
Nearly 30% of patients with schizophrenia respond inadequately to current antipsychotics, with unclear markers and mechanisms of antipsychotic efficacy. A total of 208 patients with schizophrenia treated for 6 weeks with oral paliperidone were analyz...

Novel electroencephalographic biomarkers for the prediction of responders to an experimental glutamatergic agent in patients with schizophrenia.

Translational psychiatry
All medications currently used to treat schizophrenia, which exert their therapeutic effects by inhibiting dopaminergic neurotransmission, have their greatest efficacy against the positive symptoms of schizophrenia but have limited impact on negative...

Effect of discontinuing antipsychotic medications on the risk of hospitalization in long-term care: a machine learning-based analysis.

BMC medicine
BACKGROUND: Antipsychotic medications are frequently prescribed to older residents of long-term care facilities (LTCFs) despite their limited efficacy and considerable safety risks. While discontinuation of these drugs might help reduce their associa...

Predicting clozapine-induced adverse drug reaction biomarkers using machine learning.

Scientific reports
Clozapine is an atypical antipsychotic used for patients with treatment-resistant schizophrenia. This drug has serious adverse drug reactions (ADRs), including the risk of severe neutropenia (agranulocytosis). Patients who could benefit from clozapin...

Detecting Tardive Dyskinesia Using Video-Based Artificial Intelligence.

The Journal of clinical psychiatry
Tardive dyskinesia (TD) is a late-onset adverse effect of dopamine receptor-blocking medications, characterized by involuntary movements primarily affecting the mouth, though other body parts may be involved. Severity of TD varies from mild to debil...

Longitudinal brain age in first-episode mania youth treated with lithium or quetiapine.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
It is unclear if lithium and quetiapine have neuroprotective effects, especially in early stages of bipolar and schizoaffective disorders. Here, an age-related multivariate brain structural measure (i.e., brain-PAD) at baseline and changes in respons...

Establishing a Validation Framework of Treatment Discontinuation in Claims Data Using Natural Language Processing and Electronic Health Records.

Clinical pharmacology and therapeutics
Measuring medication discontinuation in claims data primarily relies on the gaps between prescription fills, but such definitions are rarely validated. This study aimed to establish a natural language processing (NLP)-based validation framework to ev...

Deep Learning-Assisted SERS for Therapeutic Drug Monitoring of Clozapine in Serum on Plasmonic Metasurfaces.

Nano letters
Clozapine is widely regarded as one of the most effective therapeutics for treatment-resistant schizophrenia. Despite its proven efficacy, the therapeutic use of clozapine is complicated by its narrow therapeutic index, which necessitates rapid and p...

Exploring Potential Medications for Alzheimer's Disease with Psychosis by Integrating Drug Target Information into Deep Learning Models: A Data-Driven Approach.

International journal of molecular sciences
Approximately 50% of Alzheimer's disease (AD) patients develop psychotic symptoms, leading to a subtype known as psychosis in AD (AD + P), which is associated with accelerated cognitive decline compared to AD without psychosis. Currently, no FDA-appr...